EGFR and non-small cell lung carcinoma: To the best of our knowledge, the present study is the first to investigate the impact of the different lines of sequential osimertinib on clinical efficacy as the primary end point in advanced and recurrent EGFR-mutant NSCLC patients with acquired T790M mutation.